

Emanuel Christ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5078775/publications.pdf>

Version: 2024-02-01

76
papers

2,571
citations

257450

24
h-index

206112

48
g-index

79
all docs

79
docs citations

79
times ranked

2644
citing authors

#	ARTICLE	IF	CITATIONS
1	Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease) Tj ETQq1 1 0.784314 rgBT /Overlo	2.6	16
2	Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series. Clinical Endocrinology, 2022, 96, 847-856.	2.4	7
3	Molecular Imaging in neuroendocrine neoplasias. Presse Medicale, 2022, 51, 104115.	1.9	2
4	Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas. Frontiers in Endocrinology, 2022, 13, 810219.	3.5	8
5	Molecular Imaging of Neuroendocrine Neoplasms. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2662-e2670.	3.6	9
6	The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. European Journal of Cancer, 2022, 168, 80-90.	2.8	12
7	Sex-Specific Differences in Outcomes Following Thyroidectomy: A Population-Based Cohort Study. European Thyroid Journal, 2021, 10, 476-485.	2.4	2
8	Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 581-594.	5.7	29
9	Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated. Endocrine, 2021, 72, 216-222.	2.3	10
10	Influence of inferior petrosal sinus drainage symmetry on detection of adenomas in Cushing's syndrome. Journal of Neuroradiology, 2021, 48, 10-15.	1.1	16
11	Surgical Strategy Based on Radiological 3D Reconstruction in a Giant Metastatic Neuroendocrine Tumor of the Pancreas: A Case Report of an Interdisciplinary Approach. Case Reports in Surgery, 2021, 2021, 1-8.	0.4	2
12	Impact of primary medical or surgical therapy on prolactinoma patientsâ€™ BMI and metabolic profile over the long-term. Journal of Clinical and Translational Endocrinology, 2021, 24, 100258.	1.4	13
13	Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. Scientific Reports, 2021, 11, 5122.	3.3	11
14	Lateral one-third gland resection in Cushing patients with failed adenoma identification leads to low remission rates: long-term observations from a small, single-center cohort. Acta Neurochirurgica, 2021, 163, 3161-3169.	1.7	11
15	Letter to the Editor From Lukas Andereggen: "Pitfalls in Performing and Interpreting Inferior Petrosal Sinus Sampling: Personal Experience and Literature Review" Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3283-e3284.	3.6	2
16	Commentary: "Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery" Frontiers in Endocrinology, 2021, 12, 695498.	3.5	4
17	Investigating difficult to detect pancreatic lesions: Characterization of benign pancreatic islet cell tumors using multiparametric pancreatic 3-T MRI. PLoS ONE, 2021, 16, e0253078.	2.5	2
18	Safety of parathyroidectomy in older vs. younger patients with primary hyperparathyroidism. Endocrine Connections, 2021, 10, 1273-1282.	1.9	3

#	ARTICLE	IF	CITATIONS
19	New Directions in Imaging Neuroendocrine Neoplasms. <i>Current Oncology Reports</i> , 2021, 23, 143.	4.0	5
20	Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients. <i>Cancers</i> , 2021, 13, 6290.	3.7	4
21	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. <i>Annals of Surgical Oncology</i> , 2020, 27, 1348-1355.	1.5	44
22	Co-Occurrence of ANCA-Associated Vasculitis and Sjögren's Syndrome in a Patient With Acromegaly: A Case Report and Retrospective Single-Center Review of Acromegaly Patients. <i>Frontiers in Immunology</i> , 2020, 11, 613130.	4.8	5
23	Brunner's Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging. <i>Case Reports in Endocrinology</i> , 2020, 2020, 1-4.	0.4	2
24	Innovative imaging of insulinoma: the end of sampling? A review. <i>Endocrine-Related Cancer</i> , 2020, 27, R79-R92.	3.1	44
25	Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging. <i>Endocrine-Related Cancer</i> , 2020, 27, 615-624.	3.1	15
26	⁶⁸ Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5843-5852.	3.6	36
27	The effect of exercise on intramyocellular acetylcarnitine (AcCtn) concentration in adult growth hormone deficiency (GHD). <i>Scientific Reports</i> , 2019, 9, 19431.	3.3	6
28	Volume Replacement Fluid Demarks Benign Insulinoma With ⁶⁸ Ga-DOTA-Exendin-4 PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e347-e348.	1.3	7
29	AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. <i>Endocrine Connections</i> , 2019, 8, 367-377.	1.9	44
30	Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. <i>Swiss Medical Weekly</i> , 2019, 149, w14700.	1.6	10
31	Molecular imaging for neuroendocrine tumours. <i>Swiss Medical Weekly</i> , 2019, 149, w20017.	1.6	5
32	<i>MAFA</i> missense mutation causes familial insulinomatosis and diabetes mellitus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 1027-1032.	7.1	88
33	A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas. <i>Neuroendocrinology</i> , 2018, 106, 116-127.	2.5	5
34	Sensitivity Comparison of ⁶⁸ Ga-OPS202 and ⁶⁸ Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 915-921.	5.0	121
35	Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors. <i>Endocrine Connections</i> , 2018, 7, 8-15.	1.9	11
36	Impaired repletion of intramyocellular lipids in patients with growth hormone deficiency after a bout of aerobic exercise. <i>Growth Hormone and IGF Research</i> , 2018, 42-43, 32-39.	1.1	5

#	ARTICLE	IF	CITATIONS
37	A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. <i>New England Journal of Medicine</i> , 2018, 379, 428-439.	27.0	180
38	Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2318-2327.	6.4	82
39	Disturbed sphingolipid metabolism with elevated 1-deoxysphingolipids in glycogen storage disease type I â€“ A link to metabolic control. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 73-78.	1.1	7
40	A ten-year follow-up study of treatment outcome of craniopharyngiomas. <i>Swiss Medical Weekly</i> , 2018, 148, w14521.	1.6	18
41	Evaluation of the frequency of adrenal crises and preventive measures in patients with primary and secondary adrenal insufficiency in Switzerland. <i>Swiss Medical Weekly</i> , 2018, 148, w14586.	1.6	7
42	Clinical presentation of 54 patients with endogenous hyperinsulinaemic hypoglycaemia: a neurological chameleon (observational study). <i>Swiss Medical Weekly</i> , 2018, 148, w14682.	1.6	12
43	Cluster headache and macroprolactinoma: Case report of a rare, but potential important causality. <i>Journal of Clinical Neuroscience</i> , 2017, 40, 62-64.	1.5	12
44	Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health. <i>World Neurosurgery</i> , 2017, 97, 595-602.	1.3	24
45	10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. <i>Endocrine</i> , 2017, 55, 223-230.	2.3	36
46	The Flexibility of Ectopic Lipids. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1554.	4.1	26
47	Regulation of fuel metabolism during exercise in hypopituitarism with growth hormone-deficiency (GHD). <i>Growth Hormone and IGF Research</i> , 2016, 29, 39-44.	1.1	3
48	Additional malignancies in patients with neuroendocrine tumours: analysis of the SwissNET registry. <i>Swiss Medical Weekly</i> , 2016, 146, w14362.	1.6	4
49	Preoperative Glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases. <i>Patient Safety in Surgery</i> , 2015, 9, 23.	2.3	9
50	Effect of Growth hormone replacement therapy on soluble Klotho in patients with Growth hormone deficiency. <i>Clinical Endocrinology</i> , 2015, 83, 593-595.	2.4	6
51	Localization of Hidden Insulinomas with ⁶⁸ Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1075-1078.	5.0	104
52	Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance. <i>Journal of Molecular Medicine</i> , 2015, 93, 1369-1379.	3.9	23
53	Alternative nighttime nutrition regimens in glycogen storage disease type I: a controlled crossover study. <i>Journal of Inherited Metabolic Disease</i> , 2015, 38, 1093-1098.	3.6	10
54	Preoperative localization of adult nesidioblastosis using ⁶⁸ Ga-DOTA-exendin-4-PET/CT. <i>Endocrine</i> , 2015, 50, 821-823.	2.3	34

#	ARTICLE	IF	CITATIONS
55	The effect of a single 2h bout of aerobic exercise on ectopic lipids in skeletal muscle, liver and the myocardium. <i>Diabetologia</i> , 2014, 57, 1001-1005.	6.3	33
56	Integration of adult patients with phenylketonuria into professional life: Long-term follow-up of 27 patients in a single centre in Switzerland. <i>Swiss Medical Weekly</i> , 2014, 144, w14074.	1.6	5
57	Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 115-122.	11.4	153
58	Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. <i>Frontiers in Endocrinology</i> , 2012, 3, 158.	3.5	47
59	Glucocorticoid Replacement and Mortality in Patients with Nonfunctioning Pituitary Adenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1938-E1942.	3.6	74
60	Phosphorylation of sst2 Receptors in Neuroendocrine Tumors after Octreotide Treatment of Patients. <i>American Journal of Pathology</i> , 2012, 180, 1942-1949.	3.8	30
61	Selective inferior petrosal sinus sampling without venous outflow diversion in the detection of a pituitary adenoma in Cushing's syndrome. <i>Neuroradiology</i> , 2012, 54, 495-503.	2.2	18
62	Sellar collision tumor involving pituitary gonadotroph adenoma and chondroma: a potential clinical diagnosis. <i>Pituitary</i> , 2011, 14, 405-408.	2.9	12
63	Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1073-1078.	5.0	141
64	Noninvasive Assessment of Exercise-Related Intramyocellular Acetylcarnitine in Euglycemia and Hyperglycemia in Patients With Type 1 Diabetes Using 1H Magnetic Resonance Spectroscopy. <i>Diabetes Care</i> , 2011, 34, 220-222.	8.6	16
65	Regulation of whole body energy homeostasis with growth hormone replacement therapy and endurance exercise. <i>Physiological Genomics</i> , 2011, 43, 739-748.	2.3	8
66	Standardized protocol for a depletion of intramyocellular lipids (IMCL). <i>NMR in Biomedicine</i> , 2010, 23, 532-538.	2.8	24
67	Hyponatremia associated coma due to pituitary apoplexy in early pregnancy: a case report. <i>Gynecological Endocrinology</i> , 2010, 26, 197-200.	1.7	15
68	Internalized Somatostatin Receptor Subtype 2 in Neuroendocrine Tumors of Octreotide-Treated Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2343-2350.	3.6	83
69	Glucagonlike Peptide-1 Receptor: An Example of Translational Research in Insulinomas: A Review. <i>Endocrinology and Metabolism Clinics of North America</i> , 2010, 39, 791-800.	3.2	15
70	Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4398-4405.	3.6	238
71	Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Tumour/Carcinoma of the Appendix and Goblet Cell Carcinoma. <i>Neuroendocrinology</i> , 2008, 87, 20-30.	2.5	119
72	Association of 1,5-Anhydroglucitol and 2-h Postprandial Blood Glucose in Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2008, 31, 1534-1535.	8.6	71

#	ARTICLE	IF	CITATIONS
73	Glucagon-like Peptide 1â€“Receptor Scans to Localize Occult Insulinomas. New England Journal of Medicine, 2008, 359, 766-768.	27.0	181
74	Well-Differentiated Duodenal Tumor/Carcinoma (Excluding Gastrinomas). Neuroendocrinology, 2006, 84, 165-172.	2.5	70
75	Evaluation of the CCK-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - final Results of the phase 0 'Lumed' Study. Endocrine Abstracts, 0, , .	0.0	2
76	68Ga-exendin-4 PET/CT detects insulinomas in patients with hypoglycemia in multiple endocrine neoplasia type 1. Endocrine Abstracts, 0, , .	0.0	2